Advances in Relapsed/Refractory Myeloma: Keeping Pace With a Rapidly Evolving Treatment Landscape

Join expert faculty in this live, 2-hour CME-certified interactive satellite symposium exploring the latest advances in targeted and other therapies for patients with relapsed or refractory multiple myeloma.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

Agenda

6:30 – 7:00 PM Dinner and Registration

7:00 – 7:05 PM Welcome and Program Overview

7:05 – 7:35 PM Current Treatment Options at First Relapse in R/R Myeloma

7:35 – 8:05 PM Subsequent Therapy and Beyond in R/R Myeloma

8:05 – 8:35 PM Emerging and Investigational Therapies for R/R Myeloma

8:35 – 8:55 PM Audience Question and Answer Session

8:55 – 9:00 PM Closing Remarks

Faculty

Program Director
Paul G. Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research

Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Faculty
Natalie S. Callander, MD

Professor of Medicine
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Faculty
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Program Overview
This expert-led program offers clinically useful data examining the latest advances in targeted and other therapies for relapsed or refractory multiple myeloma. This will enable healthcare providers to offer optimal treatment strategies for their patients.

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with multiple myeloma.

Target Audience
This educational program is intended for medical oncologists and other HCPs who treat patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Implement therapeutic strategies with emerging agents for patients with R/R MM based on the available data and individual patient and disease characteristics
  • Explain the mechanisms of action of novel and emerging classes of agents for R/R MM
  • Assess the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Identify treatment-related symptoms associated with new targeted therapies in patients with R/R MM to create management strategies
  • Select patients with R/R MM who would be eligible for enrollment on clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.